Mentice publishes the company’s interim report for the period January – March 2023
Thursday, April 27, 2023
Increased sales and positive EBITDA conclude a good start for 2023.
Significant events during the quarter
- Two orders received from a large medical device company were announced during the quarter. The total value of these two orders together exceeded 13 MSEK.
- Abbott Laboratories, together with Medtronic, were our largest clients in the quarter, with an order volume exceeding 17MSEK.
- Alex Hussein was announced as our General Manager for the Americas region. Alex, prior to this position, held the position of Vice President of Sales for the Medical Device Industry USA, and he has been with Mentice since 2015.
FIRST QUARTER (JAN-MARCH 2023)
- Order intake amounted to 57.7 (54.4) MSEK.
- The order book by the end of the period was 126.2 (91.4) MSEK, whereof 66.2 MSEK is revenue expected in 2023.
- Net sales amounted to 65.0 (53.1) MSEK, an increase of 22%, whereof 15% organic.
- Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 7.3 (-1.3) MSEK.
- Net income for the period amounted to -1.5 (-7.4) MSEK.
- Earnings per share (EPS) were -0.06 (-0.30) SEK.
- Cash flow from operating activities totaled 1.2 (11.2) MSEK.
Webcast presentation of the interim report
To join the presentation, please visit https://investor.mentice.com.
Never miss a press release
Subscribe to automatically receive our press releases in your mailbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
